German pharmaceutical company Boehringer Ingelheim has entered a multi-year collaboration with Tempus AI (Nasdaq: TEM), ...

Boehringer will gain access to the de-identified database of Tempus, which comprises clinical, imaging and molecular data.

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

GeneDx is expanding product lines, improving margins, and increasing insurance coverage, with the recent acquisition. Read ...

On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...

If the current pace of exits persists, it would take 30 years for every U.S. company on The Crunchbase Unicorn Board to go ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...